157 related articles for article (PubMed ID: 35400000)
1. Monostotic Fibrous Dysplasia in the Femur Strongly Expressing RANKL With Concomitant Osteoporotic Vertebral Compression Fracture: A Case Report.
Azurin ES; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Yonezawa H; Morinaga S; Asano Y; Saito S; Tsuchiya H
Cancer Diagn Progn; 2022; 2(1):93-100. PubMed ID: 35400000
[TBL] [Abstract][Full Text] [Related]
2. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.
de Castro LF; Burke AB; Wang HD; Tsai J; Florenzano P; Pan KS; Bhattacharyya N; Boyce AM; Gafni RI; Molinolo AA; Robey PG; Collins MT
J Bone Miner Res; 2019 Feb; 34(2):290-294. PubMed ID: 30496606
[TBL] [Abstract][Full Text] [Related]
3. Denosumab treatment for fibrous dysplasia.
Boyce AM; Chong WH; Yao J; Gafni RI; Kelly MH; Chamberlain CE; Bassim C; Cherman N; Ellsworth M; Kasa-Vubu JZ; Farley FA; Molinolo AA; Bhattacharyya N; Collins MT
J Bone Miner Res; 2012 Jul; 27(7):1462-70. PubMed ID: 22431375
[TBL] [Abstract][Full Text] [Related]
4. Expression of RANKL in breast cancer tissue in patients with fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Majoor BCJ; Geels RES; Appelman-Dijkstra NM; Bravenboer N
Bone; 2023 Apr; 169():116679. PubMed ID: 36652988
[TBL] [Abstract][Full Text] [Related]
5. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
[TBL] [Abstract][Full Text] [Related]
6. Treatment of fibrous dysplasia: focus on denosumab.
Huzum B; Antoniu S; Dragomir R
Expert Opin Biol Ther; 2022 Mar; 22(3):397-405. PubMed ID: 34964677
[TBL] [Abstract][Full Text] [Related]
7. Expression of an active Gα
Zhao X; Deng P; Iglesias-Bartolome R; Amornphimoltham P; Steffen DJ; Jin Y; Molinolo AA; de Castro LF; Ovejero D; Yuan Q; Chen Q; Han X; Bai D; Taylor SS; Yang Y; Collins MT; Gutkind JS
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E428-E437. PubMed ID: 29282319
[TBL] [Abstract][Full Text] [Related]
8. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.
Palmisano B; Spica E; Remoli C; Labella R; Di Filippo A; Donsante S; Bini F; Raimondo D; Marinozzi F; Boyde A; Robey P; Corsi A; Riminucci M
J Bone Miner Res; 2019 Dec; 34(12):2171-2182. PubMed ID: 31295366
[TBL] [Abstract][Full Text] [Related]
9. Fibrous Dysplasia with Massive Cartilaginous Differentiation (Fibrocartilaginous Dysplasia) in the Proximal Femur: A Case Report and Review of the Literature.
Morioka H; Kamata Y; Nishimoto K; Susa M; Kikuta K; Horiuchi K; Sasaki A; Kameyama K; Nakamura M; Matsumoto M
Case Rep Oncol; 2016; 9(1):126-33. PubMed ID: 27293399
[TBL] [Abstract][Full Text] [Related]
10. RANKL inhibition halts lesion progression and promotes bone remineralization in mice with fibrous dysplasia.
Liu Z; Yin Y; Wang Z; Xie L; Deng P; Wang D; Ji N; Zhao H; Han X; Chen Q; Chung CH; Bai D; Zhao X
Bone; 2022 Mar; 156():116301. PubMed ID: 34952228
[TBL] [Abstract][Full Text] [Related]
11. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
12. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis.
Bai P; Sun Y; Jin J; Hou J; Li R; Zhang Q; Wang Y
Respir Res; 2011 Dec; 12(1):157. PubMed ID: 22176920
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
Xu S; Wang Y; Lu J; Xu J
Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
[TBL] [Abstract][Full Text] [Related]
15. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
[TBL] [Abstract][Full Text] [Related]
16. A Case Series and Literature Review of Craniofacial Fibrous Dysplasia.
Kalmegh PP; Hande A
Cureus; 2024 Mar; 16(3):e56771. PubMed ID: 38650765
[TBL] [Abstract][Full Text] [Related]
17. A pathogenic role for brain-derived neurotrophic factor (BDNF) in fibrous dysplasia of bone.
Palmisano B; Farinacci G; Campolo F; Tavanti C; Stefano A; Donsante S; Ippolito E; Giannicola G; Venneri MA; Corsi A; Riminucci M
Bone; 2024 Apr; 181():117047. PubMed ID: 38331308
[TBL] [Abstract][Full Text] [Related]
18. Fibrous dysplasia of the inferior turbinate.
Park HJ; Cho MS; Lee SS
Int J Clin Exp Pathol; 2013; 6(3):531-5. PubMed ID: 23411641
[TBL] [Abstract][Full Text] [Related]
19. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
20. Multiple calcaneal fibrous dysplasia: A case report.
Ko JH; Park GJ; Lee KB
Medicine (Baltimore); 2019 Dec; 98(51):e18389. PubMed ID: 31861003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
